GALECTIN THERAPEUTICS INC — Director's Dealing 2014

Jan 14, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GALECTIN THERAPEUTICS INC (GALT)
CIK: 0001133416
Period of Report: 2014-01-10

Reporting Person: Martin Rod D (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-01-10	Common Stock	S	42000	$16.0028	Disposed	9415422	Indirect
2014-01-13	Common Stock	S	58000	$14.0035	Disposed	9357422	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	91488	Direct

Footnotes

F1: The Issuer is aware of potential short-swing liability issues related to the transaction reported herein and a transaction reported by the Issuer's Executive Chairman that occurred on November 15, 2013. The issuer will take steps to collect any short-swing profit created by such transactions.

F2: Reflects weighted average price. Range of prices were between $15.68 and $16.35. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.

F3: Reporting Person is a managing member of 10X Capital Management, LLC, a Florida limited liability company acting as the general partner of 10X Fund, L.P., a Delaware limited partnership, and as such, may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. Mr. Martin disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F4: Reflects weighted average price. Range of prices were between $13.65 and $14.23. The reporting person will provide upon request by the Commission staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased or sold at each separate price.